KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Free Cash Flow (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Free Cash Flow for 17 consecutive years, with $58.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow fell 64.53% year-over-year to $58.9 million, compared with a TTM value of $725.0 million through Dec 2025, up 48.73%, and an annual FY2025 reading of $725.0 million, up 48.73% over the prior year.
  • Free Cash Flow was $58.9 million for Q4 2025 at Biomarin Pharmaceutical, down from $340.2 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $340.2 million in Q3 2025 and bottomed at -$98.4 million in Q1 2023.
  • Average Free Cash Flow over 5 years is $76.9 million, with a median of $69.3 million recorded in 2021.
  • The sharpest move saw Free Cash Flow plummeted 184.37% in 2022, then skyrocketed 11682.78% in 2024.
  • Year by year, Free Cash Flow stood at -$17.6 million in 2021, then plummeted by 64.61% to -$28.9 million in 2022, then surged by 95.04% to -$1.4 million in 2023, then surged by 11682.78% to $166.1 million in 2024, then crashed by 64.53% to $58.9 million in 2025.
  • Business Quant data shows Free Cash Flow for BMRN at $58.9 million in Q4 2025, $340.2 million in Q3 2025, and $168.2 million in Q2 2025.